On July 2, 1996, Masimo Corporation announced a Product Development and Licensing Agreement under which Datascope Corp. (NASDAQ:DSCP) will integrate Masimo’s pulse oximetry signal processing and sensor technologies. Datascope is a leading manufacturer of patient monitoring systems and is adopting Masimo Signal Extraction Technology (Masimo SET^®) to strengthen its core monitoring capability.

"We are impressed by the results of the preliminary clinical studies of Masimo SET," commented Lawrence Saper, Chairman and CEO of Datascope Corp. "Masimo Signal Extraction Technology represents a breakthrough in the ability to monitor patients in low perfusion states and during periods of motion. We are looking forward to the broad inclusion of Masimo SET into our patient monitoring products."

Joe E. Kiani, President and CEO of Masimo Corporation stated, "Datascope is well recognized as an innovative supplier of advanced monitoring equipment tailored to meet the challenging needs of today’s healthcare environment. Our partnership with Datascope is a further indication that Masimo SET is becoming the new standard in pulse oximetry for monitoring patients at risk of respiratory complication. We are delighted to have Datascope as a long-term partner and look forward to working with Datascope to expand the utility of pulse oximetry to new sites and applications."

Datascope Corp. manufactures proprietary products for clinical healthcare markets in interventional cardiology, anesthesiology, critical care and cardiovascular, vascular and general surgery. The company’s products, including the Passport, Accutorr and Point of View patient monitors, are distributed world-wide. Datascope is headquartered in Montvale, New Jersey.